The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.65
Bid: 0.60
Ask: 0.70
Change: 0.00 (0.00%)
Spread: 0.10 (16.667%)
Open: 0.65
High: 0.00
Low: 0.00
Prev. Close: 0.65
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

24 Aug 2011 07:00

RNS Number : 9007M
Provexis PLC
24 August 2011
 



24 August 2011

Provexis plc

 

AGM Statement

 

Provexis plc ("Provexis" or the "Company"), the life-science business that develops, licenses and markets scientifically-proven functional food, sports nutrition and medical food technologies, will hold its Annual General Meeting in Reading later today.

 

At the meeting Dawson Buck, the non-executive Chairman of the Company, will give the following update on developments:

 

 "The Company has made major progress over the past 18 months, specifically with the commercialisation of its lead technology Fruitflow and the recent acquisition of Science in Sport ("SiS").

 

Following the announcement of the long-term Alliance with DSM Nutritional Products ("DSM") in June 2010, DSM has made good progress in marketing Fruitflow to a broad range of global markets, attracting positive interest from a wide range of global, multinational and national brand owners in the functional food and dietary supplement sectors. The Alliance expects to see initial revenues from Fruitflow commence in the coming months and the Company looks forward to updating shareholders on this matter as and when appropriate.

 

The Company acquired SiS in June 2011. The Board are very pleased with the business and the opportunities it presents to the enlarged group. The Board strongly believe that through targeted investment SiS will achieve significant like for like revenue growth and margin improvement. As part of this investment the Directors expect to transfer production and distribution to a larger facility later in the year, in line with growth plans for the business. Defined marketing and selling strategies, together with new product launches and efficiencies from the supply chain, will underpin sales and profit growth in the business during 2012.

 

The SiS business presents the Company with a number of opportunities to bring new products to market to support 2012 growth; consequently the Board is currently reviewing the overall project pipeline for the Company in order to allocate resource and capital in the most effective way, in line with our growth targets.

 

We have a busy year ahead of us, with the main focus of the executive team being on delivering revenues from Fruitflow and growing the sales and profitability of the SiS business. We have sufficient resources to hand to deliver our targets and I look forward to a year of strong progress."

 

-ends-

 

For further information please contact:

 

Stephen Moon, Chief Executive

Provexis plc Tel: 01753 833177

 

Bobbie Hilliam Tel: 020 7071 4317

Evolution Securities

 

Haggie Financial LLP: Tel: 020 7417 8989

Matthew Longbottom/Peter Rigby matthew.longbottom@haggie.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMEXLFLFVFLBBB
Date   Source Headline
30th Apr 20245:00 pmRNSTotal Voting Rights
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000
29th Jan 202112:37 pmRNSHalf-year Report
31st Dec 20201:00 pmRNSTotal Voting Rights
17th Dec 20207:00 amRNS£1m placing & update re HY results
16th Nov 20207:00 amRNSExclusive Distribution Agreement for Chinese CBEC
30th Oct 20202:09 pmRNSResult of AGM
30th Sep 20207:00 amRNSFinal Results
28th Aug 20205:00 pmRNSTotal Voting Rights
13th Aug 20207:00 amRNSFruitflow® & Blood Pressure - purchase of IP
7th Aug 20205:11 pmRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
31st Dec 20197:13 amRNSInterim Results and Total Voting Rights
11th Dec 20197:00 amRNSPlacing of new ordinary shares to raise £0.301m
4th Oct 20191:19 pmRNSResult of AGM
12th Sep 20193:19 pmRNSDirector/PDMR Shareholding
11th Sep 20194:02 pmRNSGrant of Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.